MD, PhD. Nephrologist Hospital General Universitario de Valencia.
Valencia, España
Joined July 2021
- Tweets96
- Following289
- Followers109
- Likes78
Luis Carlos López Romero retweeted
En hemodiálisis, realizar sesiones de >4:00hrs, comparado a <3:15hrs; se asoció a ↓27% y ↓19% el riesgo de morir y de hospitalizarse, respectivamente
Kidney Int Rep 2026
doi.org/10.1016/j.ekir.2026.…
Luis Carlos López Romero retweeted
Todos invitados a las III Jornadas del
Grupo de Trabajo e Investigación
en Enfermedades Cardiorrenales
y Metabólicas @SVNefro @SENefrologia @prensaUCHCEU @CienciaUCHCEU @Nefro_LaFe @irisvibo @davasrodriguez @mapefer3 @reque_javier @LillyObesityInt @BoehringerES @LcLopezR
Luis Carlos López Romero retweeted
A randomized controlled trial in #ASNJASN finds that adjuvant thiazide improved diuretic response more than loop dose increased in patients with acute heart failure and diuretic resistance. Read more: kidney.pub/JASN0887
Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial - The Lancet thelancet.com/journals/lance…
1
76
Luis Carlos López Romero retweeted
‘Inside CKD’ Multinational-microsimulation Modelling Insights into the Increasing CKD Burden @KIReports
#openaccess
buff.ly/7COr5hM
Luis Carlos López Romero retweeted
Validación multicéntrica de la fórmula Kidney Failure Risk Equation (KFRE) en pacientes españoles con enfermedad renal crónica avanzada revistanefrologia.com/es-val… en #RevistaNefrología @DrMontomoli @SaraPikasso
Luis Carlos López Romero retweeted
Is Universal Healthcare a Realistic Ask for Europeans?
ms.spr.ly/6019SenDT
Luis Carlos López Romero retweeted
New in CJASN 📢
Our meta-analysis of 66 CKD trials shows both acute & chronic GFR slope independently predict clinical outcomes
Findings support 3-year total slope as the optimal surrogate endpoint for CKD trials
@asnpublications: doi.org/10.2215/CJN.00000006…
Luis Carlos López Romero retweeted
Torsemide is proposed to have clinically important pharmacokinetic and pharmacodynamic advantages over furosemide. This study found no meaningful pharmacokinetic/pharmacodynamic advantages for torsemide versus furosemide. bit.ly/JASN0481
@ClevelandClinic
@CleClinicMD
@fperrywilson
@dhekidney
ALT Visual abstract for "Mechanistic Differences between Torsemide and Furosemide."
Luis Carlos López Romero retweeted
Predialysis nephrology care and KRT-directed education (KDE) are essential for incident home dialysis use. This study found that disparities in predialysis nephrology care were significantly associated with lower home dialysis use among Hispanic and Black individuals. bit.ly/JASN0489
ALT Visual abstract for "Race- and Ethnicity-Related Disparities in Predialysis Nephrology Care, Kidney Disease Education, and Home Dialysis Utilization."
Luis Carlos López Romero retweeted
En hipertensión arterial, clortalidona, comparado a hidroclorotiazida, no fue superior en la prevención de ninguno de los eventos renales posterior a un seguimiento de 2.4 años
Ensayo clínico DCP
JAMA Network Open 2024
10.1001/jamanetworkopen.2024.49576
Luis Carlos López Romero retweeted
La estimación de la proteinuria con el cociente de proteínas/creatinina urinaria es, prácticamente perfecta, al compararlo con la recolección de 24h (AUC 0.95), certeza independiente a la función renal
Cohorte TUNARI
BMC Nephrology 2024
doi.org/10.1186/s12882-024-0…
Luis Carlos López Romero retweeted
The December 2024 issue is now available: bit.ly/AJKD2024DecTOC
Highlights:
- Cumulative Blood Pressure and CKD
- Kidney Function and Cancer Risk
- Cryoglobulin-Induced Nephropathy
- Core Curriculum: Viral Nephropathies
- Genetic Testing in Kidney Diseases: Special Report
Luis Carlos López Romero retweeted
🚑 You’re the Doctor:
A 25-year-old marathon runner collapses at the finish line. Bystanders say he was confused and agitated before collapsing. On arrival:
•BP: 88/60 mmHg
•HR: 145 bpm
•Temp: 41°C (105.8°F)
•RR: 30/min
•Skin: Hot, dry, no sweating.
What’s your next step? 🩺
A. IV fluids and antipyretics 🌡️
B. Rapid sequence intubation 🛏️
C. Ice-water immersion 🧊
D. Administer adrenaline 💉
E. CT brain to rule out stroke 🧠
👇 Comment your answer & reasoning!
#MedTwitter #FOAMed #EmergencyMedicine #MedicalEducation #MedStudentTwitter #DoctorLife #HeatStroke #CriticalCare
Luis Carlos López Romero retweeted
Albuminuria testing is an easy way to identify, early on, a higher risk of cardiovascular and kidney morbidity and mortality in patients at-risk. This study found that general practitioners (GPs) were aware of guideline recommendations to screen for albuminuria in patients with diabetes and hypertension but had difficulty interpreting the results. bit.ly/CJASN0620
ALT Visual abstract for "Obstacles and Opportunities for Albuminuria Testing Based on the Perspective of Primary Care: A Qualitative Study."
Luis Carlos López Romero retweeted
#KDOQI Commentary on @goKDIGO 2024 Clinical Practice Guideline for Evaluation & Management of CKD
bit.ly/KDOQICKD2024 (FREE)
@NishaKidneyDoc @KCavanaugh_MD @Delgadockdny @estrella_khrc @cybeleg1 @HollyMarieMD @WendyStPeter002 @KatherineTuttl8 @jwilliamMD @nkf @NKF_NephPros
Luis Carlos López Romero retweeted
Dejemos de suplementar vitamina D (cole/ergocalciferol) en personas con enfermedad renal crónica. No tiene efectos clínicos importantes cardiovasculares, óseos o inmunes.
Más cosas en contra en esta excelente revisión 👇🏼
#ISNyoung
CKJ 2024
https:/doi.org/10.1093/ckj/sfae227
Luis Carlos López Romero retweeted
Excited to share our new study on inflammation in HD patients! 🔥 Using metabolomics & LASSO, we found 🔑 differences in autophagy, arginine metab., microbiota & mitochondrial function, etc.🔍 🧪#Hemodialysis #Inflammation #metabolomics @MDPIOpenAccess
shorturl.at/h0A83
Our study on adult patients with X-linked hypophosphatemia may offer valuable insights into the natural progression in adults, which can aid in better clinical management. Here we show our results. @jbroseta @juliohe41662387 @SVNefro link.springer.com/article/10…
Luis Carlos López Romero retweeted
Sotagliflozin is a dual SGLT1 and 2 inhibitor that has demonstrated CV benefits. This study found sotagliflozin reduced the risk of kidney and cardiorenal composite end points in patients with type 2 diabetes and CKD bit.ly/CJASN0414
@AOdutayo
ALT Visual Abstract for the article titled "Sotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in Type 2 Diabetes and CKD"